✦ LIBER ✦

Characteristics and outcomes of gyn-oncology patients treated on phase I trials (1999-2012)

✍ Scribed by Slaughter, K.; James, B.; Nugent, E.; Bishop, E.; Perry, L.; McMeekin, D.; Moore, K.

Book ID: 123485222
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 217 KB
Volume: 130
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2013.04.140

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Characteristics and outcomes of platinum

Characteristics and outcomes of platinum-resistant patients treated in a phase I clinic

✍ Slaughter, K.; James, B.; Nugent, E.; Bishop, E.; Perry, L.; McMeekin, D.; Moore 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 56 KB

1252 Outcome and characteristics of pati

1252 Outcome and characteristics of patients with advanced gynaecological malignancies enrolled in phase I trials

✍ T. de La Motte Rouge; C. Gomez Roca; R. Bahleda; A. Gombos; P. Pautier; J.C. Sor 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 50 KB

1232 Impact of age on the outcome of can

1232 Impact of age on the outcome of cancer patients treated in phase I trials between 2005 and 2008

✍ C. Ferte; C. Gomez Roca; Y. Loriot; R. Bahleda; C. Moldovan; C. Massard; J.C. So 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 51 KB

Extended follow-up of outcome measures i

Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin

✍ Suzanne E. Biehn; Dominic T. Moore; Peter M. Voorhees; Reynaldo A. Garcia; Mary 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 128 KB

Thymidylate synthase, dihydropyrimidine

Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine

✍ Kazumi Uchida; Peter V Danenberg; Kathleen D Danenberg; Jean L Grem 📂 Article 📅 2008 🏛 BioMed Central 🌐 English ⚖ 569 KB

The Impact of EGFR T790M Mutations and B

The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial

✍ Costa, C.; Molina, M. A.; Drozdowskyj, A.; Gimenez-Capitan, A.; Bertran-Alamillo 📂 Article 📅 2014 🏛 American Association for Cancer Research 🌐 English ⚖ 651 KB